Introduction
Many pharmaceutical drugs work by inhibiting specific enzymes in metabolic pathways. One example is methotrexate, which is a chemotherapeutic drug used to treat certain cancers as well as autoimmune diseases like rheumatoid arthritis (Shiroky, 1997). Methotrexate is a synthetic drug that functions as an antimetabolite. The mechanism of action of methotrexate involves the competitive inhibition of the enzyme dihydrofolate reductase (DHFR), which is critical for folate metabolism and DNA synthesis. This inhibition affects folate metabolism and results in decreased DNA synthesis and cellular replication. While effective at slowing cancer growth, methotrexate can have adverse side effects like nausea and hair loss due to its disruption of folate metabolism.
Mechanism of Action
Methotrexate is a folic acid analog that has a similar structure to folate but with a critical difference that inhibits DHFR function. Methotrexate has an amino group at the 4-position of its pteridine ring, whereas folate has a hydrogen atom (Herdiana et al., 2023). This molecular difference allows methotrexate to bind to the active site of DHFR competitively, preventing folate from binding (Chango et al., 2000). When folate cannot bind, it cannot be reduced to tetrahydrofolate by DHFR. Tetrahydrofolate is a key methyl donor in the synthesis of thymidylate and purines, which are essential for DNA synthesis and cell replication (Shiroky, 1997). By inhibiting DHFR, methotrexate effectively shuts down folate metabolism and halts DNA synthesis, thus functioning as an antimetabolite chemotherapy drug.
Methotrexate is classified as a competitive inhibitor of DHFR because it competes with the substrate, folate, for binding at the enzyme’s active site. The similar molecular structure between methotrexate and folate allows methotrexate to fit into the active site, but the amino group substitution prevents catalysis. Methotrexate essentially acts as a folate mimic that binds to but does not undergo reactions with DHFR, thereby competitively blocking folate activity (Herdiana et al., 2023). This competitive binding inhibits the ability of DHFR to catalyze the reduction of folate to tetrahydrofolate, which provides the methyl groups for nucleotide biosynthesis and DNA replication. By competitively inhibiting DHFR, methotrexate brings folate-dependent metabolic processes like DNA synthesis to a halt in rapidly dividing cancer cells.
Side Effects
Since DHFR is an enzyme found in all cells of the body, methotrexate impacts normal cell replication and interferes with normal metabolism even as it preferentially targets malignant tissue. Methotrexate targets folate metabolism. Thus, it can lead to side effects associated with folate deficiency, like anemia and gastrointestinal distress. The most common side effects are nausea, vomiting, and mouth sores (Shiroky, 1997). Methotrexate also inhibits the metabolism of folic acid, which is needed for healthy hair growth, so temporary hair loss is another frequent side effect. These adverse effects result from methotrexate’s antimetabolite actions disrupting normal folate metabolism throughout the body, not just cancer cells.
For example, decreased tetrahydrofolate can lead to increased homocysteine levels, which have been associated with gastrointestinal toxicity and mucosal damage manifesting as mouth sores and nausea (Chango et al., 2000). Homocysteine disruption also interferes with hematopoiesis and red blood cell maturation, resulting in megaloblastic anemia in some patients taking methotrexate. Additionally, the role of folates in overall cellular division and regeneration underlies methotrexate effects like alopecia, skin rashes, and hepatotoxicity seen in some patients (Herdiana et al., 2023). Thus, methotrexate’s inhibition of DHFR has widespread downstream metabolic effects that can lead to adverse events affecting multiple organ systems.
Conclusion
In conclusion, methotrexate is an antimetabolite chemotherapy drug that competitively inhibits the enzyme DHFR to disrupt folate metabolism and slow cancer growth. However, its inhibition of normal folate metabolism also produces side effects like nausea and hair loss. Understanding the molecular mechanism of cancer drugs provides insight into both their therapeutic effects and adverse reactions. Tailoring treatments and providing metabolic supplementation can help mitigate methotrexate’s side effects while still harnessing its antineoplastic actions. Further research on the folate pathway may uncover additional strategies for optimizing and personalizing methotrexate therapy.
References
Chango, A., Emery-Fillon, N., de Courcy, G. P., Lambert, D., Pfister, M., Rosenblatt, D. S., & Nicolas, J. P. (2000). A polymorphism (80G-> A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Molecular genetics and metabolism, 70(4), 310-315.DOI: 10.1006/mgme.2000.3034
Herdiana, Y., Wathoni, N., Gozali, D., Shamsuddin, S., & Muchtaridi, M. (2023). Chitosan-Based Nano-Smart Drug Delivery System in Breast Cancer Therapy. Pharmaceutics, 15(3), 879. https://doi.org/10.3390/pharmaceutics15030879
Shiroky, J. B. (1997). The use of folates concomitantly with low-dose pulse methotrexate. Rheumatic Disease Clinics of North America, 23(4), 969-980. https://doi.org/10.1016/S0889-857X(05)70369-0
write